Information Provided By:
Fly News Breaks for November 12, 2019
BMRN
Nov 12, 2019 | 07:43 EDT
SunTrust analyst Robyn Karnauskas initiated coverage of BioMarin with a Buy rating and $110 price target. The analyst cites "several catalysts" for the company over the next 12-18 months, including the phase 3 data on vosoritide by the end of this year, phase 2 data on valrox by mid-2020, and indications of initial uptake for valrox by late 2020-early 2021. Karnauskas adds that her proprietary survey indicates that doctors expect the drug to be used in more patients initially and over time than what the stock currently reflects.
News For BMRN From the Last 2 Days
There are no results for your query BMRN